The Dopamine Transporter (DAT), encoded by the SLC6A3 gene, is a membrane protein responsible for the reuptake of dopamine from the synaptic cleft back into presynaptic neurons. DAT is essential for terminating dopaminergic signaling and maintaining dopamine homeostasis. Dysregulation of DAT function is a hallmark of Parkinson's Disease and contributes to motor symptoms and disease progression[1].
| Property | Value |
|---|---|
| Gene Symbol | SLC6A3 |
| Protein Name | Sodium/Dopamine Cotransporter |
| Alternative Names | DAT1, Dopamine Transporter |
| Chromosomal Location | 5p15.33 |
| Protein Class | Neurotransmitter sodium symporter (NSS) |
| Subcellular Location | Plasma membrane, primarily presynaptic terminals |
| Expression | Exclusively in dopaminergic neurons of substantia nigra and ventral tegmental area |
The SLC6A3 gene spans approximately 64 kb on chromosome 5p15.33 and contains 15 exons. Alternative splicing generates multiple transcript variants, though the predominant isoform encodes the canonical 12-transmembrane-domain protein of 619 amino acids[2]. The gene promoter contains regulatory elements responsive to neuronal activity, glucocorticoids, and various transcription factors including Npas1 and Npas2.
The DAT protein has a molecular weight of approximately 70 kDa and is heavily glycosylated at extracellular loops. Post-translational modifications include N-linked glycosylation, palmitoylation, and phosphorylation, all of which modulate its trafficking and function[3].
DAT functions as a symporter that uses the sodium gradient to transport dopamine[4]:
The transport cycle proceeds through distinct conformational states:
DAT activity is modulated by[5]:
DAT belongs to the neurotransmitter sodium symporter (NSS) family, sharing structural features with transporters for serotonin (SERT), norepinephrine (NET), and GABA (GAT1)[6]:
The bacterial leucine transporter (LeuT), a DAT homolog, has been crystallized in multiple conformational states, providing crucial insights into the transport mechanism[7]:
DAT undergoes conformational changes during the transport cycle[8]:
DAT is significantly reduced in PD[9]:
Alpha-synuclein pathology directly impacts DAT function in multiple ways[14]:
The interaction is bidirectional - DAT dysfunction also promotes alpha-synuclein aggregation through altered dopamine homeostasis.
Mitochondrial dysfunction in PD affects DAT through multiple mechanisms[15]:
ER stress in PD dopaminergic neurons contributes to DAT dysfunction[16]:
| Model | DAT Finding | Relevance |
|---|---|---|
| MPTP mice | 80% DAT binding loss | Acute degeneration model |
| 6-OHDA rats | 70% striatal DAT loss | Partial lesion model |
| α-syn Tg mice | 40% surface expression reduction | Synucleinopathy model |
| Rotenone rats | Progressive DAT decline | Mitochondrial model |
| DAT-KO mice | No DAT, compensatory changes | Knockout studies |
| Radiotracer | Target | Application | Availability |
|---|---|---|---|
| ¹²³I-FP-CIT (DaTscan) | DAT | PD diagnosis, differential diagnosis | FDA-approved |
| ¹¹¹I-ioflupane | DAT | FDA-approved for parkinsonism | FDA-approved |
| ¹¹C-raclopride | D2 receptor | Dopamine release capacity | Research |
| ¹¹C-CFT | DAT | Research applications | Research |
| ¹⁸F-FP-CIT | DAT | PET alternative | Research |
| ¹¹C-Altropane | DAT | High-affinity PET | Research |
| Pathway | Relationship |
|---|---|
| Dopamine Signaling Pathway | DAT is central to dopamine homeostasis - termination of dopaminergic signaling |
| Alpha-Synuclein Aggregation Pathway | Alpha-synuclein directly binds and inhibits DAT function |
| Oxidative Stress Pathway | Dopamine auto-oxidation causes oxidative stress, quinone formation |
| Dopamine Biosynthesis Pathway | DAT affects intracellular dopamine levels, feedback regulation |
| Mitochondrial Dysfunction Pathway | Mitochondrial toxins affect DAT function, ATP-dependent transport |
| Neuroinflammation Pathway | Cytokines modulate DAT expression and function |
| Lysosomal Dysfunction Pathway | Autophagy regulates DAT degradation |
DAT sits at the intersection of multiple homeostatic systems:
####MAO-B Inhibitors
| Target | Strategy | Status | Challenges |
|---|---|---|---|
| DAT Inhibitors | ADHD treatment (methylphenidate) | Not for PD | Would worsen PD |
| DAT Modulators | Neuroprotective agents | Preclinical | Subtype selectivity |
| Gene Therapy | AAV-DAT expression | Phase I trials | Expression control |
| Allosteric Modulators | Enhance function | Early development | Specificity |
| Trafficking Modulators | Improve membrane expression | Preclinical | Targeting |
| Degradation Inhibitors | Reduce DAT turnover | Discovery | Specificity |
| Variant | Location | Allele Frequency | Functional Effect |
|---|---|---|---|
| 3'-UTR VNTR | Exon 15 | 9-10 repeat most common | Expression modulation |
| -521C/T | Promoter | ~30% minor allele | Altered transcription |
| -67A/T | Promoter | Rare | Binding site changes |
| Val559Val | Exon 12 | Synonymous | Splicing effects |
| Gly427Glu | Exon 9 | Very rare | Early-onset PD |
| Symptom | DAT Correlation | Imaging Findings |
|---|---|---|
| Bradykinesia | Strong (r=0.7) | Putamen DAT loss |
| Rigidity | Moderate (r=0.5) | Caudate + putamen |
| Tremor | Weak (r=0.3) | Variable |
| Gait | Strong (r=0.6) | Posterior putamen |
| Postural instability | Late feature | Diffuse loss |
The Dopamine Transporter represents a central hub in Parkinson's disease pathophysiology, bridging neurotransmitter homeostasis with multiple degenerative pathways. Its dysfunction occurs early in disease progression and provides critical insights into disease mechanisms while serving as a valuable biomarker. Understanding the complex interactions between DAT, alpha-synuclein, mitochondrial dysfunction, oxidative stress, and other pathogenic processes will be essential for developing disease-modifying therapies. The convergence of advanced imaging, molecular biology, and systems neuroscience promises to advance both our understanding of PD mechanisms and the development of novel therapeutic interventions targeting DAT and related pathways.
Jaber M, et al. The dopamine transporter: a crucial component for dopaminergic neurotransmission. Trends in Neurosciences. 1996. ↩︎
Giros B, et al. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter. Molecular Pharmacology. 1992. ↩︎
Torres GE, et al. Functional diversity of dopamine transporter isoforms. Neurochemistry International. 2003. ↩︎
Gainetdinov RR & Caron MG. Dopamine transporter: voltage-dependent coupling to permeant ions. Journal of Biological Chemistry. 2003. ↩︎
Torres GE, Gainetdinov RR & Caron MG. Plasma membrane monoamine transporters: structure, regulation and function. Nature Reviews Neuroscience. 2003. ↩︎
Kristensen AS, et al. SLC6 neurotransmitter transporters: structure, function, and regulation. Pharmacological Reviews. 2011. ↩︎
Yamashita A, et al. Crystal structure of a bacterial neurotransmitter sodium symporter. Nature. 2015. ↩︎
Forrest LR & Rudnick G. The dopamine transporter: biology of a neuronally relevant transporter. Neuroscience. 2009. ↩︎
Cilia R, et al. Dopamine Transporter imaging in neurodegenerative parkinsonisms. Cell and Tissue Research. 2016. ↩︎
Bannon MJ. The dopamine transporter: potential involvement in neuropsychiatric disorders. Journal of Neurochemistry. 2005. ↩︎
Zhang S, et al. Dopamine transporter activity is modulated by alpha-synuclein. Neurobiology of Disease. 2020. ↩︎
Butler B, et al. Dopamine transporter phosphorylation and regulation. Journal of Neurochemistry. 2019. ↩︎
Hastings TG. Dopamine quinone formation in the nigrostriatal system. Methods in Enzymology. 1995. ↩︎
Bellucci A, et al. Alpha-synuclein and dopamine transporter: a pathogenic nexus in Parkinson's disease. Neuropharmacology. 2020. ↩︎
Subramaniam SR & Chesselet MF. Mitochondrial dysfunction and oxidative stress in Parkinson's disease. Current Opinion in Neurobiology. 2013. ↩︎
Ryu EJ, et al. Endoplasmic reticulum stress and the unfolded protein response in familial amyotrophic lateral sclerosis with superoxide dismutase 1 mutations. Acta Neuropathologica. 2002. ↩︎
Jackson-Lewis V, et al. Mechanism of MPTP toxicity. Parkinsonism & Related Disorders. 2000. ↩︎
Kägi G, et al. (123I)FP-CIT SPECT imaging in Parkinson's disease. Journal of Neural Transmission. 2011. ↩︎
Nutt JG, et al. Effect of levodopa on dopamine transporter. Neurology. 2004. ↩︎
Vaughan RA & Foster JD. Mechanisms of dopamine transporter function in health and disease. Trends in Pharmacological Sciences. 2013. ↩︎
Costa A, et al. Dopamine transporter gene variants and Parkinson's disease. Neurology Genetics. 2017. ↩︎
Varrone A & Halldin C. Molecular imaging of dopamine transporters. Journal of Neural Transmission. 2012. ↩︎
Ziebell M, et al. New PET radiotracers for dopamine transporters. Journal of Nuclear Medicine. 2015. ↩︎
Chung CY, et al. MicroRNA regulation of dopamine transporter. Molecular Brain. 2013. ↩︎
Barbanti P, et al. Peripheral dopamine transporter in Parkinson's disease. Neurological Sciences. 2015. ↩︎